Currently, there is no available drug that reduces tissue death during heart attack, one of the leading causes of death worldwide. MIFCOR is addressing this great need by developing a first-in-class biologic therapeutic for protecting tissue from cell death following reduced blood flow (ischemia). Our therapeutic, MIF-2, takes advantage of breakthrough science: by targeting a novel biological pathway, it protects tissue from ischemia-induced death. We have made concrete steps toward commercialization of this revolutionary therapy, including successfully executing an exclusive option on an IP portfolio, building a business plan, assembling a team of world-class advisors, and getting interest from potential investors.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mifcortx.com
Mifcor, Inc. Questions
Mifcor, Inc.'s website is http://www.mifcortx.com
Mifcor, Inc.'s LinkedIn profile is https://www.linkedin.com/company/mifcor-inc-
Mifcor, Inc.'s industry is
Biotechnology Research
Mifcor, Inc.'s top competitors are
Red Tree Venture Capital,
Atp (Apple Tree Partners),
Biotuesdays,
Flagship Pioneering,
Foxboro Capital, Llc,
Mass General Brigham Innovation,
Syenex,
Leerink Partners,
Spark Vc,
Eir Ventures.
Mifcor, Inc.'s categories are Biotechnology Research
Mifcor, Inc.'s founding year is 2014
